Anand Dubey, PhD MBA
About Anand Dubey, PhD MBA
Anand Dubey, PhD MBA, is the Associate Director of RWD Capabilities at Bristol Myers Squibb, specializing in real-world evidence research and data analytics for clinical trials.
Current Position at Bristol Myers Squibb
Anand Dubey serves as the Associate Director of RWD Capabilities at Bristol Myers Squibb, based in New Jersey, United States. His role encompasses leading the development of real-world evidence research strategies and the deployment of data analytics and research solutions for clinical trials within the pharmaceutical and biotechnology sectors. He is instrumental in building observational research concepts and implementing strategies that provide valuable insights into disease assessment and real-world treatment outcomes.
Previous Professional Experience
Anand Dubey has a comprehensive background in the field of data analytics and research within various organizations. He worked at Saama from 2018 to 2020 as a Sr. Business Solution Architect & Associate Director of RWD. Prior to that, he was at GENPACT from 2011 to 2017, holding roles as Data Analytics Manager & Engagement Manager. Earlier in his career, he was employed at Allergan as a Principal Research Associate - Global Health Outcomes Strategy from 2009 to 2011 in the Orange County, California area.
Education and Qualifications
Anand Dubey has an extensive educational background in health and pharmaceutical administration. He earned his PhD in Pharmacy Administration from the University of Louisiana at Monroe, where he studied from 2005 to 2009. Additionally, he holds a Master of Business Administration (MBA) in Health/Health Care Administration/Management from the same university. He completed his undergraduate studies at the Maharashtra Institute of Technology, achieving a Bachelor of Pharmacy (BPharm) from 1998 to 2002.
Skills in Real-World Evidence and Health Economics
Anand Dubey specializes in creating and implementing real-world evidence strategies that inform regulators, payers, and clinicians about disease progression and treatment outcomes. He has expertise in developing study plans and protocols, launching, and executing real-world evidence research projects. His work focuses on using innovative methods to meet the expectations of FDA and global regulatory agencies, and he provides both strategic and tactical support for observational and clinical research methodologies.